Who Supplies Esomeprazole to India from INDONESIA

To import finished pharmaceutical formulations containing Esomeprazole (HS Code 30049039) into India, the importing company must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves submitting an application in Form 40, along with the requisite fee, to the Drugs Controller General (I) at CDSCO. The application must include details such as the manufacturer's name and address, product composition, and manufacturing site information. Additionally, the manufacturing premises in Indonesia must be registered with CDSCO, which requires a separate application and fee. The registration process typically takes several months, depending on the completeness of the application and the need for inspections. For formulations containing Esomeprazole, specific documentation, including a Certificate of Pharmaceutical Product (CoPP) and stability data, is required. The stability data should demonstrate that the product maintains its quality under Indian climatic conditions, as per ICH guidelines. The CDSCO may also require a No Objection Certificate (NOC) from the manufacturer, authorizing the Indian importer to handle the product. It's essential to ensure that all documents are current and comply with CDSCO's standards to facilitate a smooth import process.

Imported pharmaceutical formulations containing Esomeprazole must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming that the product meets the specifications outlined in the Indian Pharmacopoeia. Stability data, demonstrating the product's shelf-life under Indian climatic conditions, is also mandatory. Upon arrival, customs drug inspectors perform port inspections to verify compliance with regulatory standards. If a batch fails to meet the required standards, it may be rejected, destroyed, or re-exported, depending on the circumstances. Importers should coordinate with authorized testing laboratories and ensure that all documentation is accurate and complete to avoid delays.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements between India and Indonesia have streamlined the import process, reducing documentation requirements and facilitating faster clearances. These changes aim to balance the promotion of domestic industry with the need for imported pharmaceuticals. Importers should stay informed about these developments to optimize their supply chain strategies.

India imports finished Esomeprazole formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as intravenous injections, are often sourced from international markets due to limited domestic production. The market size for Esomeprazole in India is substantial, with a growing number of patients requiring treatment for gastrointestinal disorders. Despite the presence of domestic manufacturers, the import dependency persists to ensure a diverse and reliable supply of these formulations.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049039 is 10%. An Education Cess of 2% and a Secondary and Higher Education Cess of 1% are applicable, totaling 3%. Additionally, an Integrated Goods and Services Tax (IGST) is levied on imports. Anti-dumping duties may apply if the product is deemed to be imported at unfairly low prices. Exemptions or concessional rates can be availed under specific trade agreements or government notifications. Importers should consult the latest customs notifications to determine the total landed duty percentage for their specific product.

India sources finished Esomeprazole formulations from Indonesia due to competitive advantages such as favorable pricing, high-quality manufacturing standards, and compliance with international regulatory requirements. Indonesia's pharmaceutical industry has established a reputation for producing reliable and cost-effective products. While other suppliers like China, Germany, and the United States also export Esomeprazole formulations to India, Indonesia's strategic location and trade agreements with India enhance its position as a preferred source. Indonesia's share in the Indian market for Esomeprazole formulations is growing, reflecting its competitive edge.

India imports finished Esomeprazole formulations from Indonesia due to strategic factors such as competitive pricing, high-quality manufacturing standards, and compliance with international regulatory requirements. Indonesia offers formulations and dosage forms that may not be readily available from domestic manufacturers, fulfilling specific market needs. The established trade relations and favorable trade agreements between the two countries further facilitate this sourcing decision.

When compared to other origins like China, the European Union, and the United States, Indonesia offers advantages in terms of cost-effectiveness and quality. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. The European Union and the United States provide high-quality products but at higher costs. Indonesia strikes a balance between quality and cost, making it an attractive sourcing option for Indian importers.

Importing finished Esomeprazole formulations from Indonesia involves risks such as single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. Past shortages have been minimal, but importers should maintain contingency plans to mitigate these risks. Diversifying suppliers and establishing robust supply chain management practices can help in managing these challenges effectively.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Neg